Zusammenfassung
In der Behandlung des Endometriumkarzinoms kommt der operativen Therapie unstrittig die zentrale Bedeutung zu. Die Hysterektomie mit beidseitiger Adnexektomie ist als Standard akzeptiert, zur Notwendigkeit einer höheren Radikalität sowohl in Bezug auf die Hysterektomie als auch die Indikationsstellung für eine pelvine und paraaortale Lymphonodektomie bei erhöhtem Rezidiv- und Metastasierungsrisiko dagegen, besteht weiterhin kein allgemeiner Konsens. Auf dem Boden einer sorgfältigen Analyse vorhandener Daten und neuer Erkenntnisse zum Ausbreitungsverhalten maligner Tumoren nehmen die Autoren eine subjektive Standortbestimmung vor und formulieren mögliche Die klassischen Behandlungsverfahren und deren Kombination werden in der internationalen NESTEC(Network Study in Endometrial Cancer)-Studie untersucht. Inwieweit sich das neue operative Konzept der radikalen Kompartment-basierten Operation (PMMR und therapeutische LNE) nach Höckel für eine Senkung lokoregionärer Rezidive auch des Endometriumkarzinoms eignet, muss ebenfalls prospektiv untersucht werden: Möglicherweise könnte die Radiatio aus der Primärtherapie vollständig herausgenommen werden und stünde so als lokoregionär hocheffektive Methode für eine Salvagetherapie beim Rezidiv zur Verfügung.
Abstract
The operative therapy indisputably plays the central role in the treatment of endometrial cancer. Hysterectomy with bilateral adnexectomy seems to be the accepted standard; however, this is contrasted by the necessity for greater radicality with respect to hysterectomy as well as indications for pelvic and para-aortic lymphadenectomy with an increased risk of recurrence and metastasis and is still a matter of intensive debate. This article presents a thorough assessment based on available data and a subjective estimation of the consequences for future therapeutic strategies. Different treatment strategies are currently investigated in the international network study in endometrial cancer (NESTEC); additional prospective trials should be carried out to evaluate whether radical compartment-based operations according to Höckel, e.g. partial mesometrial resection (PMMR) and therapeutic lymphadenectomy, are suitable for reducing local regional recurrences and also endometrial cancer. If this holds true radiation could be completely removed from the primary therapy and would then be available as a highly effective local and regional method for salvage therapy of recurrence.
Literatur
Wright JD, Barrena Medel NI, Sehouli J et al (2012) Contemporary management of endometrial cancer. Lancet 379:1352–1360
Kong A, Jahnson N, Kitchener HC, Lawrie TA (2012) Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 21:1625–1634
Scheithauer HR, Schulz DS, Belka C (2011) Endometrial cancer – reduce to the minimum. A new paradigm for adjuvant treatments? Rad Oncol 6:164–169
Johnson N, Bryant A, Miles T et al (201) Adjuvant chemotherapy for endometrial cancer after hysterectomy (review). Cochrane Database Syst Rev (10):CD003175. doi:10.1002/14651858.CD003175.pub2
Horn LC, Meinel A, Handzel R, Einenkel J (2007) Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol 11:297–311
Dowdy SC, Borah BJ, Bakkum-Gamez JN et al (2012) Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol 127:5–10
Werner HM, Trovik J, Marcickiewicz J et al (2013) A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. Eur J Cancer 49:625–632
Salvesen HB, Haldorsen IS, Trovik J (2012) Markers for individualized therapy in endometrial carcinoma. Lancet Oncol 13:e353–e361
Arora V, Quinn MA (2012) Endometrial cancer. Best Pract Res Clin Obstet Gynaecol 26:311–324
Hauspy J, Jiménez W, Rosen B et al (2010) Laparscopic surgery for endometrial cancer: a review. J Obstet Gynaecol Can 32:570–579
Acholonu UC Jr, Chang-Jackson SC, Radjabi AR, Nezhat FR (2012) Laparoscopy for the management of early-stage endometrial cancer: from experimental to standard of care. J Minim Invasive Gynecol 19:434–442
Watari H, Mitamura T, Moriwaki M et al (2009) Survival and failure pattern of patients with endometrial cancer after extensive surgery including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy. Int J Gynecol Cancer 19:1585–1590
Gadducci A, Cosio S, Fabrini MG et al (2011) Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res 31:3483–3488
Todo Y, Kato H, Minobe S et al (2011) Initial failure site according to primary treatment with or without para-aortic lymphadenectomy in endometrial cancer. Gynecol Oncol 121:314–318
Simpkins F, Papdia A, Kunos C et al (2013) Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphvascular space invasion. Int J Gynecol Cancer 23:98–104
Chen SS, Spiegel G (1991) Stage I endometrial carcinoma. Role of omental biopsy and omentectomy. J Reprod Med 36(9):627–629
Saygili U, Kavaz S, Altunyurt S et al (2001) Omentectomy, peritoneal biopsy and appendectomy in patients with clinical stage I endometrial carcinoma. Int J Gynecol Cancer 11(6):471–474
Gehrig PA, Van Le L, Fowler WC Jr (2003) The role of omentectomy during the surgical staging of uterine serous carcinoma. Int J Gynecol Cancer 13(2):212–215
Giuntoli RL 2nd, Gerardi MA, Yemelyanova AV et al (2012) Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival. Int J Gynecol Cancer 22(2):273–279. doi: 10.1097/IGC.0b013e318238df4d
Sood BM, Jones J, Gupta S et al (2003) Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.Int J Radiat Oncol Biol Phys 57(1):208–216
Dahmann C, Oates AC, Brand M (2011) Boundary formation and maintenance in tissue development. Nat Rev 12:43–55
Höckel M (2012) Cancer permeates locally within ontogenetic compartments: clinical evidence and implications for cancer surgery. Future Oncol 8(1):29–36
Heald RJ, Rayan DRH (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 327:1479–1482
Höckel M, Horn LC, Fritsch H (2005) Association between the mesenchymal compartment of uterovaginal organogenesis and local tumour spread in state 1B–2B cervical carcinoma: a prospective study. Lancet Oncol 6:751–756
Höckel M, Horn LC, Tetsch E, Einenkel J (2012) Pattern analysis of regional spread and therapeutic lymph node dissection in cervical cancer based on ontogenetic anatomy. Gynecol Oncol 125(1):168–174
Kimmig R, Iannaccone A, Buderath P et al (2013) Definition of compartment based radical surgery in uterine cancer—part I: Therapeutic pelvic and periaortic lymphadenectomy by Michael Höckel translated to robotic surgery. ISRN Obstetrics and Gynecology, srticle ID 297921, doi:10.1155/2013/297921
Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. 92:744–751
Nout RA, Smit VT, Putter H et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375(9717):816–823. doi: 10.1016/S0140-6736(09)62163-2
Marnitz S, Köhler C (2012) Current therapy of patients with endometrial carcinoma. Strahlenther Onkol 188:12–20
Creutzberg CL, Nout RA (2011) The role of radiotherapy in endometrial cancer: current evidence and trends. Curr Oncol Rep 13(6):472–478
Huh WK, Straughn JM Jr, Mariani A et al (2007) Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multi-institutional experience. Int J Gynecol Cancer 17(4):886–889
Vale CL, Tierney J, Bull SJ, Symonds PR (2012) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 8:CD003915. doi: 10.1002/14651858.CD003915.pub4
Hogberg T (2011) What is the role of chemotherapy in endometrial cancer? Curr Oncol Rep 13:413–441
Neubauer NL, Lurain JR (2011) The role of lymphadenectomy in surgical staging of endometrial cancer. Int J Surg Oncol ID 814649, 7pg
Shah PH, Kudrimoti M, Feddock J, Randall M (2011) Adjuvant treatment for stage IIIC endometrial cancer: options and controversies. Gynecol Oncol 122(3):675–683. doi: 10.1016/j.ygyno.2011.05.018 (Epub 12 Jun 2011)
Westin SN, Broaddus RR (2012) Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther 13:1–13
AlHilli MM, Podratz KC, Dowdy SC et al. (2013) Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol 128(2):294−249. doi: 10.1016/j.ygyno.2012.10.009. Epub: 2012 Oct 17.
Interessenkonflikt
Der korrespondierende Autor gibt für sich und seine Koautoren an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kimmig, R., Aktas, B. & Heubner, M. Endometriumkarzinom – operative Strategie und Adjuvanz. Gynäkologe 46, 339–344 (2013). https://doi.org/10.1007/s00129-013-3185-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00129-013-3185-z